New Trends in Clay-Based Nanohybrid Applications: Essential Oil Encapsulation Strategies to Improve Their Biological Activity

Essential oils (EOs) are used in medicinal, pharmaceutical, cosmetic, agricultural, and food industries thanks to their key properties and multiple benefits. Several techniques and embedding materials are used to nanoencapsulate EOs, in order to keep them from environmental conditions and boost their bioefficiency by controlled release. In recent years, the interest for clay nanoparticles as nanoencapsulation materials for EOs is increasing owing to their abundance in nature, low cost, inertness, and special structure. Thus, this chapter focuses on highlighting data and contributions dealing with EOs incorporation into nanoclay particles, their current applications and nanohybrid formation benefits on the stability, bioavailability, and sustained release of EOs. An overview about nanoclays used for EOs nanoencapsulation is highlighted in the beginning of this chapter followed by a brief description of EOs’ chemical composition and properties

Potential therapeutic applications of microbial surface-activecompounds

Numerous investigations of microbial surface-active compounds or biosurfactants over the past two decades have led to the discovery of many interesting physicochemical and biological properties including antimicrobial, anti-biofilm and therapeutic among many other pharmaceutical and medical applications. Microbial control and inhibition strategies involving the use of antibiotics are becoming continually challenged due to the emergence of resistant strains mostly embedded within biofilm formations that are difficult to eradicate. Different aspects of antimicrobial and anti-biofilm control are becoming issues of increasing importance in clinical, hygiene, therapeutic and other applications. Biosurfactants research has resulted in increasing interest into their ability to inhibit microbial activity and disperse microbial biofilms in addition to being mostly nontoxic and stable at extremes conditions. Some biosurfactants are now in use in clinical, food and environmental fields, whilst others remain under investigation and development. The dispersal properties of biosurfactants have been shown to rival that of conventional inhibitory agents against bacterial, fungal and yeast biofilms as well as viral membrane structures. This presents them as potential candidates for future uses in new generations of antimicrobial agents or as adjuvants to other antibiotics and use as preservatives for microbial suppression and eradication strategies

A new antibacterial and antioxidant S07-2 compound produced by Bacillus subtilis B38

An antibacterial compound, S07-2, was purified to homogeneity by hydrophobic interaction, anion exchange, C18 reverse-phase and HS PEG HPLC. The molecular mass of S07-2 was 905.6 Da as determined by MS. The S07-2 compound was resistant to high temperatures (up to 100 1C) and could withstand a wide range of pH from 3 to 10. In addition, its antibacterial activity was preserved after treatment with proteases. Biochemical characterization revealed its cyclic peptide structure. This compound showed a bactericidal effect against important food- spoilage bacteria and food-borne pathogens including Listeria monocytogenes and Enterococcus faecalis with lethal concentration values of 62.5 mg mL1 and against Salmonella enteritidis at a concentration of 31.25 mg mL1 . However, no cytotoxic effect against human erythrocytes was recorded. Furthermore, the S07-2 com- pound displayed a remarkable Fe 21 -chelating activity (EC50 = 9.76 mg mL1 ) and 1-diphenyl-2-picrylhydrazyl-scavenging capacity (IC50 = 65 mg mL1 ). All these chemical and biological features make S07-2 a useful compound in the food industry as a natural preservative

A new antibacterial and antioxidant S07-2 compound produced by Bacillus subtilis B38

International audienc

Production of Anti-Methicillin-Resistant Staphylococcus Activity from Bacillus subtilis sp Strain B38 Newly Isolated from Soil

B38 bacterial strain, isolated from Tunisian soil showed a strong antimicrobial activity. Based on biochemical characterization and 16S rDNA sequence analysis, B38 strain was identified as Bacillus subtilis. Cell culture supernatant showed antibacterial activity against clinical isolates of methicillin-resistant Staphylococcus species and several Gram-positive and Gram-negative bacteria. Antifungal activity against phytopathogenic fungi was also observed. Antibacterial activity production started at early exponential growth phase, and maximum activity was reached at the stationary phase. This antibacterial activity was neither affected by proteases, lipase, and organic solvents, nor by surfactants. It was stable over a wide pH range and still active after autoclaving at 121 degrees C during 20 min. Thin layer chromatography followed by bioautography assay allowed the detection of four active spots with R(f) values of 0.30, 0.47, 0.70, and 0.82. The single spot with R(f) 0.30 showed antifungal activity, whereas the spots with R(f) values of 0.47, 0.70, and 0.82 exhibited antibacterial activity

Antioxidant, antibacterial, and antileishmanial potential of Micromeria nervosa extracts and molecular mechanism of action of the bioactive compound

Aims: This study aimed to determine the antibacterial and antileishmanial potential of Micromeria nervosa extracts. The identification of the antileishmanial compound and the study of its molecular mechanism of action have also been undertaken. Methods and results: Ethanol extract showed high polyphenol content and diethyl ether extract exhibited high DPPH scavenging and low beta-carotene bleaching activity (IC50 = 13.04 ± 0.99 and 200.18 ± 3.32 μg mL−1 , respectively). However, diethyl ether extract displayed high antibacterial activity against Gram-positive strains including methicillin-resistant Staphylococcus aureus (MIC = 31.25 μg mL−1 ), Staph. aureus ATCC6538 (MIC = 62.5 μg mL−1 ), and Listeria monocytogenes ATCC 19115 (MIC = 125 μg mL−1 ), as well as high antileishmanial activity against the promastigote forms of L. infantum and L. major (IC50 = 11.45 and 14.53 μg mL−1 , respectively). The active compound was purified using bioassay-guided fractionation and thin layer chromatography, and identified as ursolic acid using high-performance liquid chromatography coupled with a photodiode array and mass spectrometry. The purified compound was strongly inhibitory against the promastigote and amastigote forms of L. infantum and L. major (IC50 = 5.87 and 6.95 μg mL−1 versus 9.56 and 10. 68 μg mL−1 , respectively) without overt cytotoxicity against Raw 264.7 macrophage cells (SI = 13.53 and 11.43, respectively). The commercial compound (ursolic acid) showed similar activity against amastigotes and promastigotes forms of L. infantum and L. major. Moreover, its molecular mode of action against leishmaniasis seems to involve the expression of the ODC and SPS genes involved in thiol pathway. Conclusion: Extracts of M. nervosa can be considered as a potential alternative to antimicrobial and antileishmanial drugs

Isolation of a Chitinolytic Bacillus licheniformis S213 Strain Exerting a Biological Control Against Phoma medicaginis Infection

Among nine chitinase-producing strains isolated from Tunisian soil, one isolate called S213 exhibited a potent chitinolytic activity. S213 strain was identified as Bacillus licheniformis by API 50CH system and sequence analysis of its partial 16S ribosomal DNA. Chitinolytic activity was induced either by colloidal chitin or fungal cell walls, and the highest chitinase activity reached at the late stationary phase exhibiting optimal temperature and pH of 50-60°C and pH6.0, respectively. SDS-PAGE analysis of the secreted colloidal chitin-induced proteins showed a major protein of about 65kDa. This protein was identified as chitinase on the basis of its peptide sequences which displayed high homology with chitinase sequence of B. licheniformis ATCC 14580. Moreover, chitinolytic activity containing supernatant inhibited the growth of several phytopathogenic fungi including Phoma medicaginis. Interestingly, S213 strain reduced efficiently the damping-off disease caused by P. medicaginis in Medicago truncatula and should be envisaged in enzyme-based biopesticides against phytopathogen application

Synergistic antifungal activity and potential mechanism of action of a glycolipid like compound produced by Streptomyces blastmyceticus S108 against Candida clinical isolates

Ayed A, Essid R, Mankai H, et al. Synergistic antifungal activity and potential mechanism of action of a glycolipid like compound produced by Streptomyces blastmyceticus S108 against Candida clinical isolates. Journal of Applied Microbiology . 2023: lxad246.AIM: The present study aimed to investigate a novel antifungal compound produced by Streptomyces blastmyceticus S108 strain. Its effectiveness against clinical isolates of Candida species and its synergistic effect with conventional antifungal drugs were assessed and its molecular mechanism of action was further studied against C. albicans.; METHODS AND RESULTS: A newly isolated strain from Tunisian soil, Streptomyces blastmyceticus S108, showed significant antifungal activity against Candida species by well diffusion method. The butanolic extract of S108 strain supernatant exhibited the best anti-Candida activity with a minimal inhibitory concentration (MIC) value of 250 mug mL-1, determined by the microdilution method. The bio-guided purification steps of the butanolic extract were performed by chromatographic techniques. Among the fractions obtained, F13 demonstrated the highest level of activity, displaying a MIC of 31.25 mug mL-1. Gas Chromatography-Mass Spectrometry (GC-MS) and Electrospray Ionisation Mass Spectrometry (ESI-MS) analyses of this fraction (F13) revealed the glycolipidic nature of the active molecule with a molecular weight of 685.6 m/z. This antifungal metabolite remained stable to physicochemical changes and did not show hemolytic activity even at 4 MIC corresponding to 125 g mL-1 towards human erythrocytes. Besides, the glycolipid compound was combined with 5-flucytosine and showed a high synergistic effect with a FICI value 0.14 against C. albicans ATCC 10231. This combination resulted in a decrease of MIC values of 5-flucytosine and the glycolipid-like compound by 8 and 64-fold, respectively. The examination of gene expression in treated Candida albicans cells by qPCR revealed that the active compound tested alone or in combination with 5-flucytosine blocks the ergosterol biosynthesis pathway by down regulating the expression of ERG1, ERG3, ERG5, ERG11 and ERG25 genes.; CONCLUSION AND IMPACT OF THE STUDY: The new glycolipid like compound, produced by Streptomyces S108 isolate, could be a promising drug for medical use against pathogenic Candida isolates. © The Author(s) 2023. Published by Oxford University Press on behalf of Applied Microbiology International

Utilization of Grape Seed Flour for Antimicrobial Lipopeptide Production by Bacillus amyloliquefaciens C5 Strain

International audienceAn endophytic Bacillus amyloliquefaciens strain called C5, able to produce biosurfactant lipopeptides with a broad antibacterial activity spectrum, has been isolated from the roots of olive tree. Optimization of antibacterial activity was undertaken using grape seed flour (GSF) substrate at 0.02, 0.2, and 2% (w/v) in M9 medium. Strain C5 exhibited optimal growth and antimicrobial activity (MIC value of 60 μg/ml) when incubated in the presence of 0.2% GSF while lipopeptide production culminated at 2% GSF. Thin layer chromatography analysis of lipopeptide extract revealed the presence of at least three active spots at Rf 0.35, 0.59, and 0.72 at 0.2% GSF. Data were similar to those obtained in LB-rich medium. MALDI-TOF/MS analysis of lipopeptide extract obtained from 0.2% GSF substrate revealed the presence of surfactin and bacillomycin D. These results show that GSF could be used as a low-cost culture medium supplement for optimizing the production of biosurfactants by strain C5

Triggering of the Antibacterial Activity of Bacillus subtilis B38 Strain against Methicillin-Resistant Staphylococcus aureus

International audienc